Intelligent Medicine Acquisition Corp.
IQMD
NASDAQ Global Market11.04
USD
+0.79
- -
CIK
0001850051
ISIN
US45828D1063
CUSIP
45828D106
Return %
Stock
S&P500
1Y
- -
26.84
3Y
11.97
77.03
5Y
11.97
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gregory C. Simon
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 9001 Burdette Road Bethesda MD United States of America 20817
- IPO Date
- Dec 27, 2021
- CIK
- 0001850051
- Similar Companies
- Business
- Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, with a focus on life science companies utilizing artificial intelligence, machine learning and big data for drug discovery research and development. The company, founded in 2021 and headquartered at 9001 Burdette Road in Bethesda, Maryland, conducts no significant operations and generates no revenue pending completion of an initial business combination. It targets opportunities in the healthcare and biotechnology sectors, particularly those involving AI-driven innovation in pharmaceuticals; geographically, it operates without specified regional limitations as a U.S.-based special purpose acquisition company sponsored by Intelligent Medicine Sponsor LLC. In April 2023, the company announced its intent to redeem all outstanding Class A ordinary shares at approximately $11.22 per share and liquidate after failing to consummate a business combination within the required timeframe, with redemption completed within ten business days following April 27, 2023, resulting in the company being delisted and dissolved. Previously, it completed an upsized $207 million initial public offering in November 2021, led by Cantor Fitzgerald, raising proceeds held in trust for potential deployment in a target acquisition.
Intelligent Medicine Acquisition Corp. Announces It Will Redeem Its Public Shares
Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders